Dominique Larrey Selected Research

danoprevir

10/2013	Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
1/2012	Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
8/2011	Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
6/2011	Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
12/2010	Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dominique Larrey Research Topics

Disease

26	Fibrosis (Cirrhosis) 01/2022 - 10/2002
25	Infections 01/2021 - 09/2001
17	Chronic Hepatitis C 10/2020 - 04/2002
10	Hepatitis C 06/2022 - 05/2009
9	Liver Diseases (Liver Disease) 09/2018 - 05/2006
7	Hepatitis 10/2020 - 05/2009
7	Acute Liver Failure (Fulminant Hepatic Failure) 01/2016 - 02/2005
6	Chemical and Drug Induced Liver Injury 01/2021 - 03/2011
4	Hypertension (High Blood Pressure) 02/2022 - 01/2018
4	Chronic Hepatitis B 02/2022 - 10/2016
4	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 11/2015
3	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 09/2004
3	Disease Progression 01/2022 - 06/2018
3	Neoplasms (Cancer) 11/2021 - 06/2015
3	Jaundice (Icterus) 01/2021 - 05/2009
3	Homozygous Familial Hypercholesterolemia 11/2020 - 03/2016
3	Liver Failure 01/2018 - 01/2005
3	Insulin Resistance 05/2011 - 03/2003
3	Inflammation (Inflammations) 05/2011 - 10/2004
3	Alcoholic Liver Diseases (Alcoholic Liver Disease) 11/2005 - 09/2001
2	Dyslipidemias (Dyslipidemia) 02/2022 - 01/2021
2	Ascites 01/2022 - 01/2002
2	Pruritus (Itching) 01/2021 - 01/2013
2	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/2021 - 06/2018
2	Fatty Liver 11/2020 - 03/2003
2	Asthenia 10/2020 - 01/2013
2	Coinfection 01/2019 - 09/2004
2	Wounds and Injuries (Trauma) 09/2018 - 11/2015
2	Diabetes Mellitus 01/2018 - 08/2012
2	Liver Neoplasms (Liver Cancer) 01/2018 - 08/2012
2	Hepatitis A (Hepatitis, Infectious) 01/2016 - 02/2005
2	Non-alcoholic Fatty Liver Disease 10/2014 - 05/2011
2	Iron Overload 04/2010 - 12/2007
2	Alcoholic Liver Cirrhosis (Alcoholic Cirrhosis) 05/2003 - 10/2002
1	Hydrothorax 01/2022
1	Portal Hypertension 01/2022
1	Thrombosis (Thrombus) 01/2022
1	Hepatorenal Syndrome 01/2022
1	Hemorrhage 01/2022
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022
1	Hepatopulmonary Syndrome 01/2022
1	Brain Diseases (Brain Disorder) 01/2022
1	HIV Infections (HIV Infection) 11/2021
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021
1	Communicable Diseases (Infectious Diseases) 01/2021
1	Colorectal Neoplasms (Colorectal Cancer) 11/2020

Drug/Important Bio-Agent (IBA)

23	Ribavirin (Virazole)FDA LinkGeneric 10/2020 - 04/2007
16	Antiviral Agents (Antivirals)IBA 11/2021 - 04/2002
12	InterferonsIBA 04/2019 - 09/2004
9	Pharmaceutical PreparationsIBA 01/2021 - 01/2002
7	Protease Inhibitors (Protease Inhibitor)IBA 04/2019 - 12/2010
6	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2016 - 02/2005
5	danoprevirIBA 10/2013 - 12/2010
5	RNA (Ribonucleic Acid)IBA 10/2013 - 03/2007
4	SofosbuvirIBA 01/2021 - 03/2019
4	Biomarkers (Surrogate Marker)IBA 10/2020 - 08/2010
4	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 09/2015 - 04/2007
4	peginterferon alfa-2a (Pegasys)FDA Link 02/2015 - 06/2013
4	deleobuvirIBA 10/2013 - 12/2011
3	BilirubinIBA 01/2022 - 03/2011
3	BMS201038IBA 11/2020 - 03/2016
3	daclatasvirIBA 10/2020 - 02/2015
3	Biological ProductsIBA 04/2019 - 03/2003
3	Transaminases (Aminotransferases)IBA 09/2018 - 03/2003
3	telaprevirIBA 09/2015 - 07/2014
3	SaltsIBA 09/2013 - 02/2013
3	faldaprevirIBA 06/2013 - 12/2011
3	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 03/2013 - 02/2013
2	Coffee FDA Link 02/2022 - 01/2019
2	AlbuminsIBA 01/2022 - 01/2002
2	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 01/2021 - 06/2018
2	grazoprevirIBA 01/2020 - 01/2020
2	elbasvirIBA 01/2020 - 01/2020
2	ombitasvirIBA 03/2019 - 01/2019
2	paritaprevirIBA 03/2019 - 01/2019
2	Alkaline PhosphataseIBA 09/2018 - 03/2011
2	microsomal triglyceride transfer proteinIBA 01/2017 - 03/2016
2	AntioxidantsIBA 01/2016 - 03/2003
2	Buprenorphine (Subutex)FDA LinkGeneric 12/2013 - 05/2009
2	Peptides (Polypeptides)IBA 12/2007 - 03/2007
2	Interferon-alpha (Interferon Alfa)IBA 08/2007 - 08/2002
1	A-factor (Streptomyces)IBA 06/2022
1	ABO Blood-Group SystemIBA 01/2022
1	Blood Group Antigens (Blood Groups)IBA 01/2022
1	Antifungal AgentsIBA 01/2021
1	obeticholic acidIBA 01/2021
1	Isoniazid (Ftivazide)FDA LinkGeneric 01/2021
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 01/2021
1	Fibric Acids (Fibrates)IBA 01/2021
1	LipidsIBA 11/2020

Therapy/Procedure

21	Therapeutics 01/2021 - 09/2004
12	Liver Transplantation 01/2021 - 09/2001
9	Transplantation 01/2018 - 09/2001
2	Aftercare (After-Treatment) 10/2020 - 01/2014
2	Duration of Therapy 03/2019 - 02/2015
1	Immunotherapy 01/2021
1	Drug Therapy (Chemotherapy) 11/2020
1	Adjuvant Chemotherapy 11/2020